Max M Cooper

US Patent:

20120189640, Jul 26, 2012

Filed:

Jul 27, 2007

Appl. No.:

12/375804

Inventors:

Max D. Cooper - Atlanta GA, US
Brantley R. Herrin - Decatur GA, US
Matthew N. Alder - Birmingham AL, US

Assignee:

THE UAB RESEARCH FOUNDATION - Birmingham AL

International Classification:

A61K 39/395
C07K 16/00
C12Q 1/04
C07H 21/04
C12N 15/63
C12N 5/10
C12P 21/02
G01N 33/53

US Classification:

4241641, 435 696, 5303881, 435 71, 536 2353, 4353201, 435325, 5303895, 435 34, 435 5

Abstract:

Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). More particularly, disclosed are a variety of antigen specific polypeptides, including soluble, monoclonal, and multivalent forms, as well as methods of using the polypeptides, antibodies that bind the antigen specific polypeptides, and nucleic acids, vectors and expression systems that encode the polypeptides. Antigen specific polypeptides that selectively bind pathogens, like anthrax, and carbohydrates, like blood group determinants, are specifically disclosed.

US Patent:

20200308247, Oct 1, 2020

Filed:

Apr 23, 2020

Appl. No.:

16/857130

Inventors:

- Atlanta GA, US
Max Dale Cooper - Atlanta GA, US
Rudolf Ehrhardt - Decatur GA, US

International Classification:

C07K 14/725

Abstract:

This disclosure relates to variable lymphocyte receptors (VLRs) modifications such as humanized sequences and polypeptides comprising such sequences that specifically bind a target molecule and uses related thereto. In certain embodiments, the disclosure relates to recombinant polypeptide VLRs disclosed herein and variants thereof. In certain embodiments, this disclosure relates to treating or preventing a disease or condition comprising administering an effective amount of a recombinant polypeptide or variant disclosed herein to a subject in need thereof.

US Patent:

20190256574, Aug 22, 2019

Filed:

May 1, 2019

Appl. No.:

16/400501

Inventors:

- Atlanta GA, US
Brantley R. Herrin - Decatur GA, US
Max Dale Cooper - Atlanta GA, US

International Classification:

C07K 14/705
C07K 14/725
C07K 14/46
A61K 45/06
A61K 35/17
C12N 15/85

Abstract:

This disclosure relates to recombinant cellular expression of chimeric proteins with peptide sequences derived from lymphocyte receptors and uses for treating cancer. In certain embodiments, the disclosure relates to a recombinant vector comprising a nucleic acid that encodes a chimeric protein with a segment with a targeting moiety based on a variable lymphocyte receptor (VLR) capable of binding a tumor associated antigen and a segment with a T cell signal transduction subunit. In certain embodiments, the recombinant vectors are used in immune based cancer treatments.

US Patent:

20190202887, Jul 4, 2019

Filed:

Nov 7, 2018

Appl. No.:

16/183340

Inventors:

- Atlanta GA, US
Max Dale Cooper - Atlanta GA, US
Rudolf Ehrhardt - Decatur GA, US

International Classification:

C07K 14/725

Abstract:

This disclosure relates to variable lymphocyte receptors (VLRs) modifications such as humanized sequences and polypeptides comprising such sequences that specifically bind a target molecule and uses related thereto. In certain embodiments, the disclosure relates to recombinant polypeptide VLRs disclosed herein and variants thereof. In certain embodiments, this disclosure relates to treating or preventing a disease or condition comprising administering an effective amount of a recombinant polypeptide or variant disclosed herein to a subject in need thereof.

US Patent:

20170081385, Mar 23, 2017

Filed:

Apr 30, 2015

Appl. No.:

15/308535

Inventors:

- Atlanta GA, US
Max Dale Cooper - Atlanta GA, US
Rudolf Ehrhardt - Decatur GA, US

International Classification:

C07K 14/725

Abstract:

This disclosure relates to variable lymphocyte receptors (VLRs) modifications such as humanized sequences and polypeptides comprising such sequences that specifically bind a target molecule and uses related thereto. In certain embodiments, the disclosure relates to recombinant polypeptide VLRs disclosed herein and variants thereof. In certain embodiments, this disclosure relates to treating or preventing a disease or condition comprising administering an effective amount of a recombinant poly-peptide or variant disclosed herein to a subject in need thereof.

US Patent:

20170008947, Jan 12, 2017

Filed:

Feb 9, 2015

Appl. No.:

15/117811

Inventors:

- Atlanta GA, US
Brantley R. Herrin - Decatur GA, US
Max Dale Cooper - Atlanta GA, US

International Classification:

C07K 14/705
C12N 15/85
A61K 35/17
C07K 14/725
C07K 14/46
A61K 45/06

Abstract:

This disclosure relates to recombinant cellular expression of chimeric proteins with peptide sequences derived from lymphocyte receptors and uses for treating cancer. In certain embodiments, the disclosure relates to a recombinant vector comprising a nucleic acid that encodes a chimeric protein with a segment with a targeting moiety based on a variable lymphocyte receptor (VLR) capable of binding a tumor associated antigen and a segment with a T cell signal transduction subunit. In certain embodiments, the recombinant vectors are used in immune based cancer treatments.